Eluvixtamab

艾鲁妥单抗

Report date: 2026/03/20 17:52:14

Base Information

Drug NameEluvixtamab

Drug Alias NameAMG-330MT-114

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsMyeloid cell surface antigen CD33 inhibitorsT-cell surface glycoprotein CD3 epsilon chain modulators

TargetsMyeloid cell surface antigen CD33T-cell surface glycoprotein CD3 epsilon chain

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesNetherlands +[5]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesBeOne Medicines Ltd

Inactive CompaniesAmgen Inc

Active IndicationsMyelodysplastic Syndromes

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A